Dariusz M. Kowalski

Warsaw, MZ, Poland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 118 publications

Reply to: "Beyond Response Rates: Interpreting Long-Term Benefit in CheckMate 743" and "Beyond Statistical Significance: Methodological Fragility and Censoring Bias in the 5-Year Update of CheckMate 743".

Reply to: "Beyond Response Rates: Interpreting Long-Term Benefit in CheckMate 743" and "Beyond Statistical Significance: Methodological Fragility and Censoring Bias in the 5-Year Update of CheckMate 743".

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 10, 2026

Participant-Reported Preference for Pembrolizumab Administered Subcutaneously or Intravenously: A Randomized, Open-Label, Phase II Study.

Participant-Reported Preference for Pembrolizumab Administered Subcutaneously or Intravenously: A Randomized, Open-Label, Phase II Study.

Journal: JCO oncology practice

Published: June 03, 2026

Erratum: Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743.

Erratum: Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 02, 2026

First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations.

First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations.

Journal: The New England journal of medicine

Published: May 29, 2026

First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations.

First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations.

Journal: The New England journal of medicine

Published: May 29, 2026

Corrigendum to "Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial": [Ann Oncol 36 (2025) 775-785].

Corrigendum to "Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial": [Ann Oncol 36 (2025) 775-785].

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: April 08, 2026

A phase I study evaluating subcutaneous administration of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced solid malignancies.

A phase I study evaluating subcutaneous administration of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced solid malignancies.

Journal: Cancer immunology, immunotherapy : CII

Published: March 02, 2026

Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743.

Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 24, 2026

"Variant matters": the impact of ALK fusion subtypes on progression and response in non-small-cell lung cancer-data from clinical practice from Polish centers.

"Variant matters": the impact of ALK fusion subtypes on progression and response in non-small-cell lung cancer-data from clinical practice from Polish centers.

Journal: Translational lung cancer research

Published: November 25, 2025

Clinicopathologic Characteristics, Treatment Outcomes, and Survival in Thymic Neuroendocrine Neoplasms (t-NEN): A 25-Year Single-Center Experience.

Clinicopathologic Characteristics, Treatment Outcomes, and Survival in Thymic Neuroendocrine Neoplasms (t-NEN): A 25-Year Single-Center Experience.

Journal: Cancers

Published: October 26, 2025

Best Practices and Communication Strategies for Informing Oncology Patients About Treatment Discontinuation and Transition to Palliative Care-A Practical Guide for Oncologists.

Best Practices and Communication Strategies for Informing Oncology Patients About Treatment Discontinuation and Transition to Palliative Care-A Practical Guide for Oncologists.

Journal: Cancers

Published: October 05, 2025

Trastuzumab Deruxtecan in Patients With HER2-Overexpressing NSCLC: Results From Part 1 of the Open-Label, Multicenter, Phase 1b DESTINY-Lung03 Trial.

Trastuzumab Deruxtecan in Patients With HER2-Overexpressing NSCLC: Results From Part 1 of the Open-Label, Multicenter, Phase 1b DESTINY-Lung03 Trial.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: October 03, 2025

Showing 1-12 of 118

Last Updated: 09/26/2026